Post-operative cyclic oral contraceptive use after gonadotrophin-releasing hormone agonist treatment effectively prevents endometrioma recurrence

Deuk Yong Lee, Dong-Yun Lee, Duk-Soo Bae, D-S Bae, Byung-Koo Yoon, DooSeok Choi, Dukhyun Choi
Human Reproduction · 2010 · vol. 25(12) , pp. 3050–3054 · doi:10.1093/humrep/deq279 · PMID:20937741 · W2124643065
article OA: bronze CC0 ⤵ 48 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Post-operative cyclic oral contraceptive use following GnRH agonist treatment was found to significantly reduce endometrioma recurrence compared to GnRH agonist treatment alone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Currently, no standard post-operative medical therapy has been shown to be superior in reducing the recurrence of endometrioma. This retrospective study was performed to evaluate the efficacy of post-operative cyclic oral contraceptive (OC) use after GnRH agonist (GnRHa) treatment for the prevention of endometrioma recurrence.This retrospective study included 362 reproductive-aged patients who had undergone pelviscopic surgery for endometrioma. Patients were divided into two groups: a group that received cyclic, low-dose, monophasic OCs after GnRHa treatment (n = 175) and a group that received only GnRHa treatment (n = 187). Endometrioma recurrence was evaluated by an ultrasound.During the follow-up period (median, 35 months; range, 12-114 months), recurrent endometriomas were detected in 67 patients (18.5%). Patients receiving cyclic OCs after GnRHa treatment showed a significantly reduced recurrence risk of endometrioma, when compared with patients receiving GnRHa alone (odds ratio = 0.20; 95% confidence interval, 0.10-0.38). The cumulative proportion of recurrent endometrioma after 60 months was significantly lower in OC users than in non-users (6.1 versus 43.3%; P < 0.001), and a statistically significant difference was first detected at 30 months of follow-up (5.1 versus 17.1%; P = 0.018). The number of GnRHa injections (3 versus 6) did not affect the recurrence rate for up to 60 months in OC non-users or users.Post-operative cyclic OC use after GnRHa treatment effectively reduces the recurrence of endometrioma.

My notes (saved in your browser only)

Condition tags

endometriosisendometrioma

MeSH descriptors

Contraceptives, Oral, Combined Endometriosis Gonadotropin-Releasing Hormone Contraceptives, Oral, Combined Endometriosis Endometriosis Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Postoperative Period Retrospective Studies Secondary Prevention

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (21)

Cited by (48)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:00.782903+00:00
License: CC0 · commercial use OK